Tianjin Development : Unaudited Financial Results for the nine months ended 30 September 2019 of Tianjin Lisheng Pharmaceutical Co., Ltd.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 882)

UNAUDITED FINANCIAL RESULTS

FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019 OF TIANJIN LISHENG PHARMACEUTICAL CO., LTD.

This announcement is made by Tianjin Development Holdings Limited (the "Company") pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to provide shareholders of the Company and the public with the unaudited consolidated financial results of its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) ("Lisheng Pharmaceutical"), for the nine months ended 30 September 2019.

Lisheng Pharmaceutical is a company incorporated in the People's Republic of China whose shares are listed on the Shenzhen Stock Exchange. As at the date of this announcement, the Company indirectly holds approximately 34.41% of the issued share capital of Lisheng Pharmaceutical. The unaudited consolidated income statement for the nine months ended 30 September 2019 and the unaudited condensed consolidated balance sheet as at 30 September 2019 of Lisheng Pharmaceutical prepared in accordance with China Accounting Standards for Business Enterprises are provided below:

- 1 -

Tianjin Lisheng Pharmaceutical Co., Ltd.

Consolidated Income Statement

For the nine months ended 30 September 2019

		For the nine months ended 30 September
		2019	2018
		RMB	RMB
		(unaudited)	(unaudited)
1.	Total operating income	354,224,200.36	330,545,004.27
	Including: Operating income	354,224,200.36	330,545,004.27
2.	Total operating costs	301,967,287.93	303,355,721.37
	Including: Costs of sales	91,317,614.29	86,041,303.28
	Business tax and surcharge	6,822,593.57	8,227,848.85
	Selling expenses	153,077,552.54	154,926,409.34
	Administrative expenses	31,361,237.90	28,833,392.48
	Research expenses	27,311,074.55	25,628,625.20
	Finance expenses	-7,922,784.92	-301,857.78
	Including: Interest expenses	1,225,491.67	1,321,651.40
	Interest income	9,176,333.92	1,651,555.56
	Add: Other income	206,850.47	―
	Investment income	1,255,531.06	14,911,792.85
	Including: Investment income from associates
	and joint ventures	1,255,531.06	2,761,792.85
	Impairment losses on assets	39,160.52	―
	Income from disposal of assets	―	-27,594.01
3.	Operating profit	53,758,454.48	42,073,481.74
	Add: Non-operating income	645,070.50	511,067.13
	Less: Non-operating expenses	278,772.04	102,404.26
4.	Total profit	54,124,752.94	42,482,144.61
	Less: Income tax expenses	8,216,494.66	6,323,353.89
5.	Net profit	45,908,258.28	36,158,790.72
	Net profit attributable to owners of parent company	45,908,258.28	36,158,790.72
6.	Other comprehensive income, net of tax	―	―
7.	Total comprehensive income	45,908,258.28	36,158,790.72
	Total comprehensive income attributable to
	owners of parent company	45,908,258.28	36,158,790.72
8.	Earnings per share:
	(1) Basic earnings per share (RMB/share)	0.25	0.20
	(2) Diluted earnings per share (RMB/share)	0.25	0.20

- 2 -

Tianjin Lisheng Pharmaceutical Co., Ltd.

Condensed Consolidated Balance Sheet

As at 30 September 2019

	At 30 September		At 31 December
	2019	2018
	RMB		RMB
	(unaudited)		(audited)
ASSETS
Current assets	2,393,558,422.21	2,302,027,950.38
Non-current assets	3,226,508,898.03	1,615,173,597.11
Total assets	5,620,067,320.24	3,917,201,547.49
LIABILITIES
Current liabilities	704,322,051.14	684,792,895.81
Non-current liabilities	262,833,053.92		20,053,339.65
Total liabilities	967,155,105.06	704,846,235.46
OWNERS' EQUITY
Share capital	182,454,992.00	182,454,992.00
Capital reserves	1,691,564,108.23	1,691,564,108.23
Other comprehensive income	1,363,072,737.09	5,068,372.00
Special reserves	15,436,360.96	12,510,530.31
Surplus reserves	374,057,331.92	374,057,331.92
Undistributed profit	1,026,326,684.98	946,699,977.57
Total equity attributable to owners of
parent company	4,652,912,215.18	3,212,355,312.03
TOTAL OWNERS' EQUITY	4,652,912,215.18	3,212,355,312.03
TOTAL LIABILITIES AND
OWNERS' EQUITY	5,620,067,320.24	3,917,201,547.49

- 3 -

Shareholders of the Company should note that the above unaudited financial information pertains only to Lisheng Pharmaceutical and not to the Company itself.

Details of the unaudited consolidated financial results of Lisheng Pharmaceutical for the nine months ended 30 September 2019 are available on the website of Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board

Tianjin Development Holdings Limited

Wang Zhiyong

Chairman and Executive Director

Hong Kong, 25 October 2019

As at the date of this announcement, the board of directors of the Company consists of Mr. Wang Zhiyong, Mr. Chen Yanhua, Dr. Li Xiaoguang, Mr. Zhuang Qifei, Mr. Cui Xiaofei, Mr. Cheung Wing Yui, Edward*, Dr. Chan Ching Har, Eliza*, Dr. Cheng Hon Kwan**, Mr. Mak Kwai Wing, Alexander**, Ms. Ng Yi Kum, Estella**, Mr. Wong Shiu Hoi, Peter** and Dr. Loke Yu**.

• non-executivedirector
• independent non-executive director

- 4 -